Volume 28, Number 7—July 2022
Dispatch
Multisystem Inflammatory Syndrome after Breakthrough SARS-CoV-2 Infection in 2 Immunized Adolescents, United States
Lyndsey D. Cole, Molly Slate, Samantha Minneman, and Michael J. Bozzella
Table 2
Infectious laboratory results for 2 adolescents after multisystem inflammatory syndrome in children symptom onset and throughout hospitalization, United States*
| Laboratory test | Case-patient 1 | Case-patient 2 |
|---|---|---|
| SARS-CoV-2 spike IgG | Positive | NA |
| SARS-CoV-2 nucleocapsid IgG | Positive | Positive |
| SARS-CoV-2 PCR | Negative | Positive† |
| Other respiratory pathogen panel PCR | Negative | Negative |
| Blood culture, peripheral, 2 sets | Negative | Negative |
| Urine culture | Negative | Negative |
| Epstein Barr virus ab panel | Consistent with prior infection | Negative |
| Gastrointestinal pathogen panel PCR | Negative | NA |
| Group A Streptococcus throat PCR | Negative | NA |
| Quantiferon tuberculosis gold | Negative | NA |
| HIV Ag/Ab, 4th-generation | NA | Nonreactive |
| Rapid plasma regain | NA | Nonreactive |
| Parvovirus IgM and IgG | NA | Negative |
| Anti-streptolysin-O | NA | Negative |
| Anti-deoxyribonuclease B | NA | Negative |
*Ag, antigen; Ab, antibody. †Case-patient 2 had a positive SARS-CoV-2 PCR result on day-of-illness 11, followed by a negative result on day-of-illness 19.
Page created: May 04, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.